



(JunHe) Provides services in a variety of industries, including energy, electronics and healthcare. Actively participates in the drafting and amendment of relevant laws and regulations.

—Chambers Asia-Pacific

Pharmaceuticals

Pharmaceutical products are used to prevent, diagnose and treat diseases, and are subject to the Drug Administration Law of the People's Republic of China, the Implementing Regulations of the Drug Administration Law of the People's Republic of China, and other laws and regulations. In recent years, to adapt to the rapid development of the pharmaceutical industry, the breadth and intensity of drug regulatory reform in China has escalated dramatically, and the pace of China's integration with the international drug regulatory system has increased significantly.

JunHe's dedicated team has years of experience serving the pharmaceutical industry. With an in-depth understanding of the pharmaceutical industry, a broad client base and a good relationship with industry regulators, the scope of our service can cover all aspects of drug research and development, manufacturing, and commercialization. With experienced personnel from many different departments, our team can provide a one-stop service for pharmaceutical enterprises in areas such as regulatory, corporate and M&A, capital market, private equity/venture capital, intellectual property, compliance and dispute resolution.

We can provide the following legal services in the pharmaceutical industry:

- Regulatory. We are able to not only provide regulatory legal services in relation to clinical trials, drug registration, and GCP/GMP compliance for drug development and manufacturing enterprises, but we can also advise on marketing, promotion, distribution, bidding and tendering, adverse drug reaction monitoring, and product recall. We can design and evaluate the optimal path for drug registration and commercialization for our clients, according to the latest drug review policies.
- Pharmaceutical licensing transactions. We have participated in many complex transactions that have involved drugs that are in the R&D stage or have been marketed. We have first-hand experience in cross-border co-development and licensing transactions for drug products.
- Pharmaceutical co-development and commercial transactions. We have assisted many pharmaceutical companies in different types of cooperative transactions with their business partners, leveraging their respective strengths through various structure and cooperation models, including joint ventures, co-developments and promotional collaborations, to accelerate the commercial value of our their products.
- Pharmaceutical M&A transactions. We have assisted many multinational pharmaceutical, biopharma and biotech companies in their equity and asset merger and acquisition transactions, helping them to integrate their supply chain and expand their business, and to achieve rapid growth through M&A. Private equity and capital markets. Our clients include well-known investment institutions committed to the pharmaceutical sector, such as Sequoia, Qiming, Warburg Pincus, CITIC Capital and Ping An. We have also assisted many leading biotech companies, as well as listed companies who have achieved outstanding results in the pharmaceutical industry. We have participated in the listing of companies such as BeiGene, Shanghai Pharma, Xinhua Pharmaceutical and NT Pharma.
- Intellectual property. With a professional team of lawyers from our Silicon Valley, Shanghai, Beijing and Guangzhou offices, we can provide trans-regional, comprehensive and professional services for numerous innovative drug research and development companies across the country. We have had exceptional results in cases involving patent protection (including patent applications) and dispute resolution involving intellectual property.
- Compliance. Our compliance services cover drug regulatory compliance, anti-trust compliance, anti-commercial bribery compliance, privacy protection and data security compliance. In addition to assisting clients in internal compliance investigations, we have vast experience in dealing with law enforcement actions by government agencies and have established positive working relationships with law enforcement agencies and are appreciated by clients for providing constructive and feasible solutions.

JunHe, founded in Beijing in 1989, is one of the first private partnership law firms in China. Since its establishment, JunHe has grown to be a large and recognized Chinese law firm. The firm has fourteen offices around the world and a team comprised of more than a thousand professionals.



(JunHe) Acts for clients in a variety of industries and is increasingly active in the pharmaceutical and health-care sectors.

—Chambers Asia-Pacific

Selected Deals

GuoDa Drugstore introduced international strategic investors with a capital increase of RMB 2.7667 billion

JunHe represented China National Accord Medicines Corporation Ltd. and provided legal services for its subsidiary, Sinopharm GuoDa Drugstore Co., Ltd, to receive RMB 2.7 billion from an international strategic investor. This was China's largest cross-border joint venture in the pharmaceutical retail industry to date. JunHe provided the client with efficient, comprehensive and constructive legal services, including designing the transaction structure, assisting in the preparation of the transaction documents, participating in the drafting and negotiation of the contracts.

HD Biosciences Co., Ltd. sold its 100% Equity

JunHe assisted HD Biosciences Co., Ltd. in its sale of 100% equity to Wuxi AppTech. Headquartered in Shanghai, HD Biosciences is a leading pre-clinical research and development service platform in the industry. Acting as the PRC legal counsel to HD Biosciences and its original shareholders, JunHe fully participated in the early discussion, negotiations and revision of the transaction documents, as well as the final closing. JunHe assisted the company in arranging and coordinating the exit of different shareholders (including Pfizer, Lilly, Morningside Venture Capital, and other investors) and assisted in handling its domestic and overseas employee shareholding platform.

JD.com and Shanghai Pharma Jointly Build an Online Medical Sale Platform

Shanghai Pharma Health Commerce Co., Ltd. is a medical E-commerce platform developed by Shanghai Pharma. It is a prescription medicine O2O E-commerce platform combining online and offline resources, integrating services and trades, with "Internet+" as its core concept, to build three online platforms and an offline three-tier network. JunHe represented Beijing Jingdong Century Trade Co., Ltd. in the completion of the Series A financing for Shanghai Pharma Health Commerce Co., Ltd.

Series A Financing from Temasek for JW Biotechnology Co. Ltd.

JW Biotechnology Co. Ltd. is an innovative biotechnology company focused on the latest cell-therapy technology. It has introduced the products and the technical platform of Juno to China, and its CAR-T product JWCAR029 successfully applied for a clinical trial with the former China Food and Drug Administration. JunHe represented Temasek in the joint leading investment with Sequoia and Yuanming Capital in the USD 90 million Series A financing for JW Biotechnology.

Series B Financing from Temasek for Hangzhou Just Biotherapeutics Inc.

JunHe represented Temasek in the Series B Financing for Hangzhou Just Biotherapeutics Inc., and rendered legal services including legal due diligence investigation, reviewing and revising the PRC transaction documents, as well as attending negotiations. This project involved a complex dual shareholding structure at both the Cayman level and the PRC level and was ranked by SINA as one of the top 10 investment and financing events in the China healthcare industry in 2017.

PAG's Investment in Rongchang Pharmaceuticals

JunHe represented PAG in its successful RMB 1 billion financing for Rongchang Pharmaceuticals Ltd. Rongchang Pharmaceuticals Ltd. is a modern pharmaceutical enterprise integrating the R&D, production, and sales of modern Chinese medicine and biological drugs. Its ADC new anti-tumor drug RC48 was the first ADC drug in China to be approved by the former China Food and Drug Administration to enter into clinical trials for human subjects.

Law Firms of the Year -
Healthcare, Pharma & Life Sciences
2022

Deals of the Year - BeiGene's
USD3.2bn IPO on Star Market
2022

Deals of the Year -
Abogen Therapeutics Series
C and C+ Financing
2022

Deals of the Year -
AstraZeneca, Aosaikang Patent
Infringement Dispute
2022

China Business Law Awards/
China Business Law Deals of the Year

Equity Deal of the Year -
BeiGene's IPO
2022

ALB Hong Kong Law Awards

Deals of the Year - Shanghai -
Banking and Finance - China
Biologic Products Holdings USD4.8
billion Take-private Financing
2022

IFLR 1000 China Awards

Firm of the Year - Healthcare
2022

ALB China Law Awards

As one of the few domestic teams that provide specialized legal services in the life sciences and healthcare industry, JunHe offers comprehensive, full-range professional services for various clients in the industry, including multi-national corporations, private equity/venture investment institutions, medical institutions, listed companies, large- and medium-sized enterprises and innovative enterprises with growing capacity.